PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

192 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... 5 ... 6 ... 7 ... 8 ... 9 ... 10 ... ▶▶ ▶▮
Alle Publikationen dieser Seite in den Korb legen
61.
Reiter, K. et al.: Tyrosin kinase inhibition restores the membrane localization of FLT3-ITD. Blood 126 (2015)
62.
Yu, X.* et al.: Antigen-armed antibodies targeting B lymphoma cells effectively activate antigen-specific CD4+ T cells. Blood 125, 1601-1610 (2015)
63.
Bigalke, I.* et al.: Vaccination with a new generation of fast dendritic cells transfected with mRNA from hTERT, survivin and autologous tumor mount strong immune responses and prolong survival. Blood 124 (2014)
64.
Boettcher, S.* et al.: Endothelial cells translate pathogen signals into G-CSF-driven emergency granulopoiesis. Blood 124, 1393-1403 (2014)
65.
Bruns, H.* et al.: Vitamin D-dependent induction of cathelicidin in human macrophages results in cytotoxicity against high grade B-cell lymphoma. Blood 124 (2014)
66.
Calvo-Vidal, N.* et al.: Hsp90 at the hub of metabolic homeostasis in malignant B cells. Blood 124 (2014)
67.
Dutta, S. et al.: Analysis of the tissue-specific expression requirements and identification of cooperating mutations for leukemogenesis in an inducible CALM/AF10 knock-in mouse model. Blood 124 (2014)
68.
Hartmann, L. et al.: Genetic evolution of Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) during therapy and relapse: An exome sequencing study of 47 cases. Blood 124 (2014)
69.
Herold, T. et al.: Isolated trisomy 13 defines a genetically homogenous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis. Blood 124, 1304-1311 (2014)
70.
Hoellein, A.* et al.: Myc commands an aurora kinase - sumoylation circuit required for B cell lymphoma growth and survival. Blood 124 (2014)
71.
Hutter, G. et al.: Combination of PI3K and PDPK1 inhibitors is highly effective in mantle cell lymphoma. Blood 124 (2014)
72.
Jeremias, I. et al.: Bioluminescence in vivo imaging improves the model of individual patients' AML cells growing in mice for sensitive and reliable preclinical treatment trials on various genetic subgroups. Blood 124 (2014)
73.
Jost, P.J.* et al.: A mouse model for XLP-2 disease uncovers a critical function for IL-1beta and TNF in driving hyper-inflammation. Blood 124 (2014)
74.
Krupka, C. et al.: CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood 123, 356-365 (2014)
75.
Li, L.S.* et al.: Type II JAK2 inhibitor NVP-CHZ868 is active in vivo against JAK2-dependent B-Cell Acute Lymphoblastic Leukemias (B-ALLs). Blood 124 (2014)
76.
Stemberger, C.* et al.: Lowest numbers of primary CD8+ T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood 124, 628-637 (2014)
77.
Tassara, M.* et al.: Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. Blood 123, 4027-4036 (2014)
78.
von der Heide, E.K.* et al.: Molecular alterations in bone marrow mesenchymal stroma cells of AML patients. Blood 124 (2014)
79.
Vosberg, S. et al.: Copy Number Alteration (CNA) analysis in targeted sequencing data from Acute Myeloid Leukemia (AML) patients with chromosome 9q deletion. Blood 124 (2014)
80.
Krappmann, D.: Shaping oncogenic NF-κB activity in the nucleus. Blood 122, 2146-2147 (2013)
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... 5 ... 6 ... 7 ... 8 ... 9 ... 10 ... ▶▶ ▶▮